Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection

Journal of Gastroenterology

Volumn 50, Issue 8, 2015, Pages 894-902

  Aoki, Yoshihiko ^a   Sugiyama, Masaya ^a   Murata, Kazumoto ^a   Yoshio, Sachiyo ^a   Kurosaki, Masayuki ^b   Hashimoto, Satoru ^c   Yatsuhashi, Hiroshi ^c   Nomura, Hideyuki ^d   Kang, Jong Hon ^e   Takeda, Tsutomu ^f   Naito, Shigeko ^g   Kimura, Tatsuji ^g   Yamagiwa, Yoko ^a   Korenaga, Masaaki ^a   Imamura, Masatoshi ^a   Masaki, Naohiko ^a   Izumi, Namiki ^b   Kage, Masayoshi ^h   Mizokami, Masashi ^a   Kanto, Tatsuya ^a  

^a National Center for Global Health and Medicine   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Shin Kokura Hospital   (Japan)

^e TEINE KEIJINKAI HOSPITAL   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Institute of Immunology Co Ltd   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine; Hepatitis C virus; IL 28B; Interferon 3; Pegylated interferon plus ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; INTERFERON; INTERFERON LAMBDA 3; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; AUTACOID; BIOLOGICAL MARKER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOLUMINESCENCE; CHRONIC HEPATITIS C; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; ADULT; AGED; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84938956201     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-1023-2     Document Type: Article

References (36)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–8.
2. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41(1):17–27.
3. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907–17.
4. Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future. N Engl J Med. 2014;370(21):2043–7.
5. Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):S88–100.
6. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9.e18.
7. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
8. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.
10. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887–98.
11. Kotenko SV. IFN-λs. Curr Opin Immunol. 2011;23(5):583–90.
12. Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978–88.
13. Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40(1):8–13.
14. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.
15. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15–20.
16. Ogawa E, Furusyo N, Shimizu M, et al. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antivir Ther. 2014. doi:10.3851/IMP2805.
17. Teshale E, Lu M, Rupp LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014;21(12):917–20.
18. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49(5):1853–60.
19. Sugiyama M, Kimura T, Naito S, et al. Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon. Hepatol Res. 2012;42(11):1089–99.
20. Melton AC, Yee HF. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology. 2007;45(6):1446–53.
21. Wasmuth HE, Tag CG, Van de Leur E, et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology. 2009;49(3):775–80.
22. Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res. 2010;40(11):1128–41.
23. Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology. 2012;56(6):2060–70.
24. + dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology. 2013;57(5):1705–15.
25. Stone AE, Giugliano S, Schnell G, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 2013;9(4):e1003316.
26. Pott J, Mahlakoiv T, Mordstein M, et al. IFN-λ determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011;108(19):7944–9.
27. Sugiyama M, Tanaka Y, Wakita T, et al. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One. 2011;6(10):e26620.
28. McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15(1):72–9.
29. Langhans B, Kupfer B, Braunschweiger I, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54(5):859–65.
30. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360–9.
31. You CR, Park SH, Jeong SW, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver. 2011;5(4):506–12.
32. Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54(6):2076–88.
33. Patsenker E, Popov Y, Wiesner M, et al. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46(5):878–87.
34. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617–25.
35. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011;53(1):14–22.
36. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6(2):e17232.